Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI)

Modern Rheumatology

Volumn 23, Issue 2, 2013, Pages 318-322

  Yokogawa, Naoto ^a   Tanikawa, Akiko ^b   Amagai, Masayuki ^b   Kato, Yukihiko ^a   Momose, Yoko ^c   Arai, Satoru ^c   Eto, Hikaru ^c   Ikeda, Takaharu ^d   Furukawa, Fukumi ^d  

^a TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Cutaneous lupus erythematosus; Cutaneous lupus erythematosus disease area and severity index (CLASI); Hydroxychloroquine; Systemic lupus erythematosus

Indexed keywords

ANTIRHEUMATIC AGENT; HYDROXYCHLOROQUINE;

ADOLESCENT; ADULT; ARTICLE; ASIAN; FEMALE; HUMAN; JAPAN; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; SKIN LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIRHEUMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYDROXYCHLOROQUINE; JAPAN; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84883151129     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-012-0656-3     Document Type: Article

References (20)

1. Yokogawa N. Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/anti-rheumatic drugs; 10. Hydroxychloroquine. Nihon Naika Gakkai Zasshi. 2011;100:2960-5 (in Japanese).
2. Kishimoto M, Deshpande GA, Yokogawa N, Buyon JP, Okada M. Hydroxychloroquine in Japan: a newly rising sun. J Rheumatol. 2012 (in press).
3. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125: 889-94.
4. Yokogawa N, Kato Y, Sugii S, Inada S. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). Mod Rheumatol. 2011 [Epub ahead of print].
5. Ikeda T, Kanazawa N, Furukawa F. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. J Dermatol. 2011 [Epub ahead of print].
6. Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis. 1982;8: 207-18.
7. Sontheimer RD, McCauliffe DP. Lupus-specific skin disease (cutaneous LE). In: Wallace DJ, Hahn WB, editors. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 576-620.
8. Klein R, Moghadam-Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147: 203-8.
9. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
10. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133: 1433-40.
11. Albrecht J, Werth VP. Clinical outcome measures for cutaneous lupus erythematosus. Lupus. 2010;19: 1137-43.
12. Jessop S, Whitelaw DA, Delamere FM. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev. 2009;4:CD002954.
13. Dubois E. Antimalarials in the management of discoid and systemic erythematosus. Semin Arthritis Rheum. 1978;8: 33-51.
14. Tsuchida T. Classification of lupus erythematosus based upon Japanese patients. Autoimmun Rev. 2009;8: 453-5.
15. Piette EW, Foering KP, Chang AY, Okawa J, Ten Have TR, Feng R, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol. 2011 [Epub ahead of print].
16. Kreuter A, Gaifullina R, Tigges C, Kirschke J, Altmeyer P, Gambichler T. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch Dermatol. 2009;145: 244-8.
17. Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges. 2010;8: 829-44.
18. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus. Ann Rheum Dis. 2010;69: 20-8.
19. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010;62: 775-84.
20. Marmor MF, Kellner U, Lai TY, Lyons JS, American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118: 415-22.